Skip to Content
Merck
All Photos(1)

Key Documents

SML0414

Sigma-Aldrich

NCX 4040

≥98% (HPLC)

Synonym(s):

2-(Acetyloxy)benzoic acid 4-(nitroxymethyl)phenyl ester, NO-aspirin

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C16H13NO7
CAS Number:
Molecular Weight:
331.28
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

protect from light

color

white to beige

solubility

DMSO: 15 mg/mL (clear solution)

storage temp.

−20°C

SMILES string

CC(=O)Oc1ccccc1C(=O)Oc2ccc(CO[N+]([O-])=O)cc2

InChI

1S/C16H13NO7/c1-11(18)23-15-5-3-2-4-14(15)16(19)24-13-8-6-12(7-9-13)10-22-17(20)21/h2-9H,10H2,1H3

InChI key

CTHNKWFUDCMLIQ-UHFFFAOYSA-N

Biochem/physiol Actions

NCX 4040 is a nitric oxide-donating form of aspirin. NCX 4040 inhibits cyclooxygenase activity and releases NO, which can down-regulate COX2 expression and reduce the levels of superoxide accumulation. In the human monocytic cell line THP1, the compound inhibits PGE2 production and cytokine expression, and appears to stabilize IkB by inhibiting proteasome function. NCX 4040 has been shown to induce apoptosis in several tumor cell lines.

Features and Benefits

This compound is featured on the Nitric Oxide Synthases page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Signal Word

Danger

Hazard Statements

Hazard Classifications

Aquatic Acute 1 - Eye Dam. 1 - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Anna Tesei et al.
Journal of translational medicine, 5, 52-52 (2007-11-01)
Despite numerous studies aimed at verifying the antitumor activity of nitric oxide-releasing nonsteroidal antiflammatory drugs (NO-NSAIDs), little is known about the molecular targets responsible for their antineoplastic properties. In the present study, we investigated the mechanisms underlying the cytotoxicity of
Jung Min Song et al.
Carcinogenesis, 39(7), 911-920 (2018-07-10)
Although regular aspirin use has been shown to lower the risk of colorectal cancer, its efficacy against lung cancer is weak or inconsistent. Moreover, aspirin use increases the risk of ulcers and stomach bleeding. In this study, we determined the
Massimiliano Marvasi et al.
AMB Express, 6(1), 49-49 (2016-07-28)
Recent studies suggest that nitric oxide donors capable of manipulating nitric oxide-mediated signaling in bacteria could induce dispersal of biofilms. Encased in extracellular polymeric substances, human and plant pathogens within biofilms are significantly more resistant to sanitizers. This is particularly
Paul Guedeney et al.
Journal of clinical medicine, 9(3) (2020-03-07)
The respective ischemic and bleeding risks of early aspirin discontinuation following an acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) remain uncertain. We performed a prospero-registered review of randomized controlled trials (RCTs) comparing a P2Y12 inhibitor-based single antiplatelet strategy
Anna Tesei et al.
Journal of translational medicine, 3(1), 7-7 (2005-02-05)
BACKGROUND: Nitric oxide-releasing nonsteroidal antiinflammatory drugs (NO-NSAIDs) are reported to be safer than NSAIDs because of their lower gastric toxicity. We compared the effect of a novel NO-releasing derivate, NCX 4040, with that of aspirin and its denitrated analog, NCX

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service